{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T16:21:41Z","timestamp":1784737301613,"version":"3.55.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>This study aims to understand the relationship between Lifetime Classic Psychedelic Use (LCPU), employment status, and weekly work hours on levels of psychological distress. The data used for this analysis is pooled from the National Survey of Drug Use and Health (NSDUH) from 2008\u20132019 and includes a sample size of 484,732 individuals. The findings suggest that LCPU and being employed are independently associated with better health. Additionally, the results indicate that psychedelic use is associated with lower distress for those who are employed, volunteer, retired, or permanently disabled. However, those who are unemployed, full-time students, or homemakers may experience higher levels of distress with psychedelic use. Interestingly, the analysis also suggests that those who use psychedelics are working longer hours per week before experiencing an increase in stress. Overall, the study suggests that psychedelics are not likely to have a negative impact on employment outcomes.<\/jats:p>","DOI":"10.3389\/fpsyt.2023.1186541","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T04:41:34Z","timestamp":1686890494000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Psychedelics and workplace harm"],"prefix":"10.3389","volume":"14","author":[{"given":"Sean Matthew","family":"Vi\u00f1a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Layne","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"ref1","volume-title":"National Survey on Drug Use and Health (NSDUH)","year":"2021"},{"key":"ref2","volume-title":"Thousands of moms are microdosing with mushrooms to ease the stress of parenting","author":"Sherry","year":"2022"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1021\/acsptsci.1c00024","article-title":"On the relationship between classic psychedelics and suicidality: a systematic review","volume":"4","author":"Zeifman","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jpsychires.2022.03.008","article-title":"MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD","volume":"149","author":"Brewerton","year":"2022","journal-title":"J Psychiatr Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer","year":"2019","journal-title":"Psychopharmacology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s40429-021-00401-8","article-title":"Novel treatment approaches for substance use disorders: Therapeutic use of psychedelics and the role of psychotherapy","volume":"9","author":"Koslowski","year":"2021","journal-title":"Curr Addict Rep"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2021.687546","article-title":"Cross-sectional associations between lifetime use of psychedelic drugs and psychometric measures during the COVID-19 confinement: a transcultural study","volume":"12","author":"R\u00e9v\u00e9sz","year":"2021","journal-title":"Front Psych"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"103380","DOI":"10.1016\/j.drugpo.2021.103380","article-title":"Classic psychedelics in the treatment of substance use disorder: potential synergies with twelve-step programs","volume":"98","author":"Yaden","year":"2021","journal-title":"Int J Drug Policy"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1161\/HYPERTENSIONAHA.120.16715","article-title":"Association between lifetime classic psychedelic use and hypertension in the past year","volume":"77","author":"Simonsson","year":"2021","journal-title":"Hypertension"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"14427","DOI":"10.1038\/s41598-021-93787-4","article-title":"Associations between lifetime classic psychedelic use and cardiometabolic diseases","volume":"11","author":"Simonsson","year":"2021","journal-title":"Sci Rep"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/0269881121996863","article-title":"Associations between lifetime classic psychedelic use and markers of physical health","volume":"35","author":"Simonsson","year":"2021","journal-title":"J Psychopharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/0269881113513851","article-title":"Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision","volume":"28","author":"Hendricks","year":"2014","journal-title":"J Psychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/0269881117735685","article-title":"The relationships of classic psychedelic use with criminal behavior in the United States adult population","volume":"32","author":"Hendricks","year":"2018","journal-title":"J Psychopharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"204512532211353","DOI":"10.1177\/20451253221135363","article-title":"Classic psychedelics, health behavior, and physical health","volume":"12","author":"Simonsson","year":"2022","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/jcad.12429","article-title":"Counselors\u2019 attitudes toward psychedelics and their use in therapy","volume":"100","author":"Hearn","year":"2022","journal-title":"J Couns Dev"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"109399","DOI":"10.1016\/j.neuropharm.2022.109399","article-title":"The varieties of psychedelic law","volume":"226","author":"Marks","year":"2023","journal-title":"Neuropharmacology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","article-title":"The current status of psychedelics in psychiatry","volume":"78","author":"Nutt","year":"2021","journal-title":"JAMA Psychiat"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1542\/peds.2009-0467","article-title":"Violence, abuse, and crime exposure in a National Sample of children and youth","volume":"124","author":"Finkelhor","year":"2009","journal-title":"Pediatrics"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.scitotenv.2018.06.368","article-title":"Heat wave and the risk of intimate partner violence","volume":"644","author":"Sanz-Barbero","year":"2018","journal-title":"Sci Total Environ"},{"key":"ref25","author":"Poznyak","year":"2018"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/epirev\/mxaa006","article-title":"Drug use disorders and violence: associations with individual drug categories","volume":"42","author":"Zhong","year":"2020","journal-title":"Epidemiol Rev"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J Psychopharmacol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-981-16-7084-8_15","article-title":"Set, setting, and clinical trials: colonial technologies and psychedelics","volume-title":"The Palgrave handbook of the anthropology of technology","author":"Dummit","year":"2022"},{"key":"ref29","first-page":"652","article-title":"Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy","volume-title":"Transcult Psychiatry","author":"Gukasyan","year":"2021"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"205032451668332","DOI":"10.1177\/2050324516683325","article-title":"Constructing drug effects: a history of set and setting","volume":"3","author":"Hartogsohn","year":"2017","journal-title":"Drug Sci Policy Law"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1177\/13634615221100385","article-title":"Modalities of the psychedelic experience: microclimates of set and setting in hallucinogen research and culture","volume":"59","author":"Hartogsohn","year":"2022","journal-title":"Transcult Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1353\/ppp.2021.0032","article-title":"Containment matters: set and setting in contemporary psychedelic psychiatry","volume":"28","author":"Noorani","year":"2021","journal-title":"Philos Psychiatry Psychol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1021\/acsptsci.0c00187","article-title":"Set and setting: a randomized study of different musical genres in supporting psychedelic therapy","volume":"4","author":"Strickland","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1556\/2054.2019.022","article-title":"Race as a component of set and setting: how experiences of race can influence psychedelic experiences","volume":"4","author":"Neitzke-Spruill","year":"2019","journal-title":"J Psychedelic Stud"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/0269881111420188.Mystical","article-title":"Psilocybin Lead to increases in the personality domain of openness","volume":"25","author":"Maclean","year":"2011","journal-title":"J Psychoph"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2307\/2626958","article-title":"Social conditions as fundamental causes of disease author","volume":"35","author":"Link","year":"2009","journal-title":"J Health Soc Behav"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1177\/0022146510383498","article-title":"Social conditions as fundamental causes of health inequalities: theory, evidence, and policy implications","volume":"51","author":"Phelan","year":"2010","journal-title":"J Health Soc Behav"},{"key":"ref39","article-title":"Mortality in the United States, 2020","volume-title":"National Center for Health Statistics","author":"Murphy","year":"2021"},{"key":"ref40","article-title":"Binge drinking among adults, by select characteristics and state-United States, 2018","volume":"15","author":"Bohm","year":"2021","journal-title":"Morb Mortal Wkly Rep"},{"key":"ref41","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:106273","article-title":"NHSR 158. National Health and nutrition examination survey 2017\u2013March 2020 pre-pandemic data files","author":"Bryan","year":"2021"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1017\/S0033291702006074","article-title":"Short screening scales to monitor population prevalences and trends in non-specific psychological distress.","volume":"32","author":"Kessler","year":"2002","journal-title":"Psychol Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/mpr.310","article-title":"Screening for serious mental illness in the general population with the K6 screening scale: Results from the WHO World Mental Health (WMH) survey initiative","volume":"19","author":"Kessler","year":"2010","journal-title":"Int J Methods Psychiatr Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","article-title":"Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews","volume":"11","author":"dos Santos","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyg.2021.729425","article-title":"Psychedelics, sociality, and human evolution","volume":"12","author":"Rodr\u00edguez Arce","year":"2021","journal-title":"Front Psychol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2015.00358","article-title":"Psychedelics and immunomodulation: novel approaches and therapeutic opportunities","volume":"6","author":"Szabo","year":"2015","journal-title":"Front Immunol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0269881114565653","article-title":"Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population","volume":"29","author":"Hendricks","year":"2015","journal-title":"J Psychopharmacol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/02698811211058923","article-title":"MDMA\/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults","volume":"36","author":"Jones","year":"","journal-title":"J Psychopharmacol"},{"key":"ref50","volume-title":"Regression models for categorical dependent variables using Stata","author":"Long","year":"2014"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/02698811211058933","article-title":"Psilocybin use is associated with lowered odds of crime arrests in US adults: a replication and extension","volume":"36","author":"Jones","year":"","journal-title":"J Psychopharmacol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"11353","DOI":"10.3390\/ijerph191811353","article-title":"Association between lifetime classic psychedelic use and sick leave in a population-based sample","volume":"19","author":"Mellner","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.1111\/opo.12131","article-title":"When to use the Bonferroni correction","volume":"34","author":"Armstrong","year":"2014","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref54","volume-title":"The myth of psychedelic exceptionalism","author":"Marlan","year":"2021"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1186541\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T04:41:42Z","timestamp":1686890502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1186541\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":54,"alternative-id":["10.3389\/fpsyt.2023.1186541"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1186541","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"article-number":"1186541"}}